Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Seizures and Epilepsy: Overview and Classification : Article by

Epilepsy Resource Center
Epilepsy Resource Center

View all Epilepsy Articles

Epilepsy Multimedia Library


Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Cardioembolic Stroke

Confusional States and Acute Memory Disorders

Febrile Seizures

First Seizure in Adulthood: Diagnosis and Treatment

First Seizure: Pediatric Perspective

Frontal Lobe Epilepsy

Idiopathic Orthostatic Hypotension and other Autonomic Failure Syndromes

Migraine Headache

Somnambulism (Sleep Walking)

Transient Global Amnesia




Patient Education
Brain and Nervous System Center

Epilepsy Overview

Epilepsy Causes

Epilepsy Symptoms

Epilepsy Treatment




Author: Jose E Cavazos, MD, PhD, Assistant Professor, Departments of Medicine (Neurology), Pharmacology, and Physiology, University of Texas Health Science Center at San Antonio

Jose E Cavazos is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, and Society for Neuroscience

Coauthor(s): Frank Lum, MD, Instructor, Department of Neurology, University of Colorado Health Sciences Center; Mark Spitz, MD, Professor, Department of Neurology, University of Colorado Health Sciences Center

Editors: Ramon Diaz-Arrastia, MD, PhD, Assistant Professor, Department of Neurology, Comprehensive Epilepsy Center, University of Texas Southwestern; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital; Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital; Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants

Author and Editor Disclosure

Synonyms and related keywords: spells, convulsions, attacks, seizures, epilepsy, epileptic seizures, overview of seizures and epilepsy, classification of seizures, classification of epilepsy, partial-onset seizures, generalized-onset seizures, unclassified seizures, epileptic syndromes

Background

Epileptic seizures have been recognized for millennia. One of the earliest descriptions of a secondarily generalized tonic-clonic seizure was recorded over 3000 years ago in Mesopotamia. The seizure was attributed to the god of the moon. Epileptic seizures were described in ancient cultures, including those of China, Egypt, and India. An ancient Egyptian papyrus described a seizure in a man who had previous head trauma. Hippocrates wrote the first book about epilepsy almost 2500 years ago. He rejected ideas regarding the divine etiology of epilepsy and concluded that the cause was excessive phlegm that caused abnormal brain consistency. Hippocratic teachings were forgotten, and divine etiologies again dominated beliefs about epileptic seizures during medieval times. Even at the turn of the 19th century, excessive masturbation was considered a cause of epilepsy. This hypothesis is credited as leading to the use of the first effective anticonvulsant (ie, bromides).

Modern investigation of the etiology of epilepsy began with the work of Fritsch, Hitzig, Ferrier, and Caton in the 1870s. They recorded and evoked epileptic seizures in the cerebral cortex of animals. In 1929, Berger discovered that electrical brain signals could be recorded from the human head by using scalp electrodes; this discovery led to the use of electroencephalography (EEG) to study and classify epileptic seizures. Gibbs, Lennox, Penfield, and Jasper further advanced the understanding of epilepsy and developed the system of the 2 major classes of epileptic seizures currently used. An excellent historical review of seizures and epilepsy, written by E. Goldensohn, was published in the journal Epilepsia to commemorate the 50th anniversary of the creation of the American Epilepsy Society in 1997. A more recent review discusses the foundation of this professional society.1

Definitions

Epilepsy is a disorder characterized by the occurrence of at least 2 unprovoked seizures 24 hours apart. Some clinicians are also diagnosing epilepsy when 1 unprovoked seizure occurs in the setting of an interictal discharge. Seizures are the manifestation of abnormal hypersynchronous discharges of cortical neurons. The clinical signs or symptoms of seizures depend on the location of the epileptic discharges in the cortex and the extent and pattern of the propagation of the epileptic discharge in the brain.

That seizures are a common, nonspecific manifestation of neurologic injury and disease should not be surprising because the main function of the brain is the transmission of electrical impulses. The lifetime likelihood of experiencing at least 1 epileptic seizure is about 9%, and the lifetime likelihood of receiving a diagnosis of epilepsy is almost 3%. However, the prevalence of active epilepsy is only about 0.8%.

This article reviews the classifications, pathophysiology, clinical manifestations, and treatment of epileptic seizures and some common epileptic syndromes. Several articles in this electronic journal of neurology are dedicated particularly to epileptic syndromes and their treatment. They are not reviewed in this introductory article. Related articles in the Neurology section of the eMedicine journal are the following:

  • Seizure types and other conditions

Simple Partial Seizures Complex Partial Seizures

Tonic-Clonic Seizures

Absence Seizures

Seizure, Pseudo

Shuddering Attacks

First Seizure in Adulthood: Diagnosis and Treatment

First Seizure: Pediatric Perspective

Epilepsia Partialis Continua

Status Epilepticus

Preeclampsia and Eclampsia

  • Epileptic syndromes and epilepsy treatment

Benign Childhood Epilepsy

Benign Neonatal Convulsions

Driving and Neurological Disease

EEG in Common Epilepsy Syndromes

Epilepsy, Juvenile Myoclonic

Epileptic and Epileptiform Encephalopathies

Epilepsy in Adults with Mental Retardation

Epilepsy in Children with Mental Retardation

Febrile Seizures

Frontal Lobe Epilepsy

Identification of Potential Epilepsy Surgery Candidates

Lennox-Gastaut Syndrome

Outcome of Epilepsy Surgery

Neuroimaging in Epilepsy Surgery

Neonatal Seizures

Posttraumatic Epilepsy

Presurgical Evaluation of Medically Intractable Epilepsy

Psychiatric Disorders Associated with Epilepsy

Reflex Epilepsy

Sudden Unexpected Death in Epilepsy

Temporal Lobe Epilepsy

Vagus Nerve Stimulation

Women's Health and Epilepsy

Classification of epileptic seizures

In 1981, the International League Against Epilepsy (ILAE) developed an international classification of epileptic seizures that divides seizures into 2 major classes: partial-onset seizures and generalized-onset seizures. Partial-onset seizures begin in a focal area of the cerebral cortex, whereas generalized-onset seizures have an onset recorded simultaneously in both cerebral hemispheres. Some seizures are difficult to fit into a single class, and they are considered unclassified seizures. This classification is still widely accepted. 

Other classifications, such as the semiological classification advanced by Luders and others, have been proposed.2 A refinement of this semiological classification led to a 5-dimensional patient-oriented classification of epilepsy.3 The ILAE commission on classification has developed additional reports4, 5, but no proposed new revisions to the 1981 classification have been made. 

Partial-onset seizures

Partial-onset seizures are further classified as simple partial seizures, complex partial seizures, or secondarily generalized tonic-clonic seizures.

The defining element of simple partial seizures is a seizure with preserved consciousness. Many patients with complex partial seizures have an aura warning them of their seizure. An aura is a simple partial seizure. The many kinds of simple partial seizures include sensory, motor, autonomic, and psychic types. Any discrete experience that involves the cerebral cortex could be a simple partial seizure. The diagnosis is based on the repeated, stereotypic occurrence of the same experience in association with focal EEG changes or on recurrent auras leading to a complex partial seizure or a secondarily generalized seizure. Resolution of the recurrent clinical phenomena with anticonvulsants is presumptive but not diagnostic evidence for epileptic seizures.

The clinical diagnosis is difficult, as many stereotypic auras may be induced in areas of the cerebral cortex that are not recorded well on a typical EEG. About 20-40% of auras have an ictal correlate on the scalp EEG. Simple partial seizures may last a few seconds to a few minutes. However, if the aura lasts longer than 30 minutes, it is considered simple partial status epilepticus by definition.

Consciousness is impaired during a complex partial seizure. In practice, assessing the patient's history to determine whether consciousness was impaired is difficult. The most common way to assess preserved consciousness is asking patients if they remembered the event. Patients might be able to remember their aura but are unaware that they were briefly unable to respond to the environment. A complex partial seizure typically begins with behavioral arrest and is followed by staring, automatisms, and postictal confusion. Automatisms frequently consist of chewing, lip smacking, mumbling, and fumbling with the hands. Dystonic posturing of the contralateral upper extremity is often seen when a complex partial seizure originates from the mesial temporal lobe. A typical complex partial seizure lasts about 60-90 seconds and is followed by brief postictal confusion. However, generalized weakness, asthenia, and fatigue may last for a few days.

Complex partial seizures of frontal-lobe origin may feature bizarre motor behaviors such as bicycling or a fencing posture. They have more prominent motor features than those of complex partial seizures of temporal-lobe onset. Frontal lobe onset complex partial seizures might have a fast postictal recovery to baseline, and often they appear in clusters of seizures. The great majority of complex partial seizures have an ictal correlate on the EEG. A normal alpha rhythm during behavioral impairment of consciousness is highly suggestive of nonepileptic seizures.

Secondarily generalized seizures often begin with an aura that evolves into a complex partial seizure and then into a generalized tonic-clonic seizure. However, a complex partial seizure may evolve into a generalized tonic-clonic seizure, or an aura may evolve into a generalized tonic-clonic seizure without an obvious complex partial seizure. Clinically classifying a generalized tonic-clonic seizure as being secondarily generalized (partial onset) or primarily generalized is difficult on the basis of the history alone. In most cases, the association with prominent amnesia for the aura increases with the severity of a secondarily generalized seizure.

Generalized-onset seizures

Generalized-onset seizures are classified into 6 major categories: (1) absence seizures, (2) tonic seizures, (3) clonic seizures, (4) myoclonic seizures, (5) primary generalized tonic-clonic seizures, and (6) atonic seizures.

Absence seizures are brief episodes of impaired consciousness with no aura or postictal confusion. They typically last less than 20 seconds and are accompanied by few or no automatisms. Facial automatisms are most common, and repetitive blinking is the most common facial automatism. Hyperventilation or photic stimulation often precipitates these seizures which typically begin during childhood or adolescence, though they may persist into adulthood. A diagnosis of new-onset absence seizures in adulthood is incorrect in the vast majority of cases. Adults often have complex partial seizures with relatively minor automatisms. In children, absence seizures are often unrecognized until a child develops a generalized tonic-clonic seizure and is brought to medical attention. Sudden decreased performance in school or overall attention might be a subtle manifestation of frequent absence seizures.

The classic ictal EEG correlate of absence seizures consists of 3.5-Hz generalized spike-and–slow wave complexes. Twin studies have demonstrated a significant inherited predisposition for typical childhood absence seizures. EEG abnormalities may persist into adulthood despite the absence of clinical seizures. However, compared with the EEG discharges in children, those in adults occur less often, they are less well formed, and they are of lesser amplitude.

Myoclonic seizures consist of brief, arrhythmic, jerking, motor movements that last less than a second. Myoclonic seizures often cluster within a few minutes. If they evolve into rhythmic, jerking movements, they are classified as evolving into a clonic seizure. Myoclonus is not always epileptic in origin. For example, the myoclonic jerks during phase I of sleep are normal release phenomena. The classic ictal correlate of myoclonic seizures in the EEG consists of fast polyspike-and–slow wave complexes.

Clonic seizures consist of rhythmic, motor, jerking movements with or without impairment of consciousness. Clonic seizures can have a focal origin with or without impaired consciousness. The focal seizures are classified as simple or complex partial seizures. The typical generalized clonic seizures simultaneously involve the upper and lower extremities. The ictal EEG correlate consists of bilateral rhythmic epileptiform discharges.

Tonic seizures consist of sudden-onset tonic extension or flexion of the head, trunk, and/or extremities for several seconds. These seizures typically occur in relation to drowsiness, shortly after the person falls asleep, or just after he or she awakens. They are often associated with other neurologic abnormalities. The ictal correlate of tonic seizures in the EEG includes an electrodecremental response, which is a high-frequency electrographic discharge in the beta frequency (also known as "beta buzz") with a relatively low amplitude compared with that of the background rhythm. This pattern may evolve into slow spike-and-wave complexes or diffuse polyspikes.

Tonic-clonic seizures are commonly referred to as grand mal seizures. They consist of several motor behaviors, including generalized tonic extension of the extremities lasting for few seconds followed by clonic rhythmic movements and prolonged postictal confusion. On clinical evaluation, the only behavioral difference between these seizures and secondarily generalized tonic-clonic seizures is that these seizures lack an aura. However, the aura preceding the secondarily generalized seizure is often forgotten because of postictal amnesia. The ictal correlate of generalized tonic-clonic seizures consists of generalized (bilateral) complexes of spikes or polyspike and slow waves. These epileptiform discharges often have increased amplitude in the frontal regions.

Atonic seizures occur in people with clinically significant neurologic abnormalities. These seizures consist of brief loss of postural tone, often resulting in falls and injuries. The ictal EEG correlate is similar to abnormalities observed in tonic seizures.

Unclassified seizures

Each seizure type is classified by its clinical and EEG manifestations. On occasion, classifying seizures is difficult despite videotape review of the data.

Classification of epileptic syndromes

Epileptic seizures are symptoms of neurologic dysfunction and are but one manifestation of many neurologic diseases. Like any other syndrome in medicine, an epileptic syndrome is a group of signs and symptoms that share a common pathogenesis, prognosis, and response to treatment.

In 1989, the ILAE developed a classification of epileptic syndromes. At present, a task force is revising this syndromic classification. The current system comprises 2 major categories: localization-related syndromes and generalized-onset syndromes. Physicians would ideally classify their patients' seizures by using the classification for seizure types and make a syndromic diagnosis if possible.

Pathophysiology

Seizures are paroxysmal manifestations of the electrical properties of the cerebral cortex. A seizure results when a sudden imbalance occurs between the excitatory and inhibitory forces within the network of cortical neurons in favor of a sudden-onset net excitation. If the affected cortical network is in the visual cortex, the clinical manifestations are visual phenomena. Other affected areas of primary cortex give rise to sensory, gustatory, or motor manifestations. The pathophysiology of partial-onset seizures differs from the mechanisms underlying generalized-onset seizures. Overall, cellular excitability is increased, but the mechanisms of synchronization appear to substantially differ and are therefore discussed separately. For a recent review, please see the epilepsy book of Rho, Sankar and Cavazos.6

Partial-onset seizures

The clinical neurophysiologic hallmark of partial-onset seizures is the focal interictal epileptiform spike or sharp wave. The cellular neurophysiologic correlate of an interictal epileptiform discharge in single cortical neurons is the paroxysmal depolarization shift (PDS). The PDS is characterized by a prolonged calcium-dependent depolarization that results in multiple sodium-mediated action potentials during the depolarization phase, and it is followed by a prominent after hyperpolarization, which is a hyperpolarized membrane potential beyond the baseline resting potential. Calcium-dependent potassium channels mostly mediate the after-hyperpolarization phase. When multiple neurons fire PDSs in a synchronous manner, the extracellular field recording shows an interictal spike.

If the number of discharging neurons is more than several million, they can usually be recorded with scalp EEG electrodes. Calculations show that the interictal spikes need to spread to about 6 cm2 of cerebral cortex before they can be detected with scalp electrodes. Several factors may be associated with the transition from an interictal spike to an epileptic seizure. When any of the mechanisms that underlie an acute seizure become a permanent alteration, patients are assumed to then develop a propensity for recurrent seizures (ie, epilepsy).

Mechanisms leading to decreased inhibition

Mechanisms leading to decreased inhibition include defective gamma-aminobutyric acid (GABA)-A inhibition, defective GABA-B inhibition, defective activation of GABA neurons, and defective intracellular buffering of calcium.

Defective GABA-A inhibition: GABA is the main inhibiting neurotransmitter in the brain. GABA binds to 2 major classes of receptors: GABA-A and GABA-B. GABA-A receptors are coupled to chloride channels, and they are one of the main targets modulated by the anticonvulsants that are currently available. The reversal potential of chloride is about -70 mV. The contribution of chloride channels during resting potential in neurons is minimal because at the typical resting potential, which is near -70 mV, no significant electromotive force exists for net chloride flux. However, chloride currents become more important at more depolarized membrane potentials. These channels make it difficult to achieve the threshold membrane potential necessary for an action potential. Their influence in the neuronal membrane potential increases, as the neurons become more depolarized by summation of the excitatory postsynaptic potentials (EPSPs).

Properties of the chloride channels associated with the GABA-A receptor are often clinically modulated by using benzodiazepines (eg, diazepam, lorazepam, clonazepam), barbiturates (eg, phenobarbital, pentobarbital), or the anticonvulsive drug topiramate. Benzodiazepines increase the frequency of openings of chloride channels, whereas barbiturates increase the duration of openings of these channels. Topiramate increases the frequency of channel openings but binds to a site different from the benzodiazepine-receptor site. Either benzodiazepines or barbiturates, but not both, appear to modulate individual chloride channels. Whether combining topiramate with either class of agents increases the chloride currents is unknown.

Alterations in the normal state of the chloride channels described above increase membrane permeability and conductance of chloride ions. In the end, the behavior of all individual chloride channels sum to form a large chloride-mediated hyperpolarizing current that counterbalances the depolarizing currents created by summation of EPSPs induced by activation of the excitatory input.

The EPSPs are the main form of communication between neurons, and the release of the excitatory amino acid glutamate from the presynaptic element mediates EPSPs. Three main receptors mediate the effect of glutamate release in the postsynaptic neuron: N-methyl-D-aspartic acid (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate, and metabotropic, which are coupled by means of different mechanisms to several depolarizing channels. Inhibitory postsynaptic potentials (IPSPs), mediated mainly by the release of GABA in the synaptic cleft with postsynaptic activation of GABA-A receptors, temper these effects.

All channels in the nervous system (and essentially any living organism) appear to be subject to modulation by several mechanisms, such as phosphorylation and possibly a change in the tridimensional conformation of a protein in the channel. The chloride channel has several phosphorylation sites, one of which topiramate appears to modulate. Phosphorylation of this channel induces a change in normal electrophysiologic behavior, with an increased frequency of channel openings but for only certain chloride channels. Each channel has a multimeric structure with several subunits of different types. Chloride channels are no exception; they have a pentameric structure. The subunits are molecularly related but different proteins.

The heterogeneity of electrophysiological responses of different GABA-A receptors is due to different combinations of the subunits. In mammals, at least 6 alpha subunits and 3 beta and gamma subunits exist for the GABA-A receptor complex. A complete GABA-A receptor complex (which in this case is the chloride channel itself) is formed from 1 gamma, 2 alpha, and 2 beta subunits. The number of possible combinations of the known subunits is almost 1000; therefore, more than 1000 receptor types theoretically exist.

In practice, only about 20 of these combinations have been found in the normal mammalian brain. Some epilepsies may be due to mutations or lack of expression of the different GABA-A receptor complex subunits, the molecules that govern their assembly, or the molecules that modulate their electrical properties. For example, hippocampal pyramidal neurons might not be able to assemble alpha 5/beta 3/gamma 3 receptors because of deletion of chromosome 15 (ie, Angelman syndrome).

Changes in the distribution of subunits of the GABA-A receptor complex have been demonstrated in several animal models of partial-onset epilepsy, such as the electrical-kindling, chemical-kindling, and pilocarpine models. In the last model, decreased concentrations of mRNA for the alpha 5 subunit of the surviving interneurons were observed in the CA1 region of the rat hippocampus.7

Defective GABA-B inhibition: The GABA-B receptor is coupled to potassium channels, forming a current that has a relatively long duration of action compared to the chloride current evoked by activation of the GABA-A receptor. Because of the long duration of action, alterations in the GABA-B receptor are thought to possibly play a major role in the transition between the interictal abnormality and a partial-onset seizure. The molecular structure of the GABA-B receptor complex consists of 2 subunits with 7 transmembrane domains each.

G proteins, a second messenger system, mediate coupling to the potassium channel, explaining the latency and long duration of the response. In many cases, GABA-B receptors are located in the presynaptic element of an excitatory projection. Therefore, release of GABA from the interneuron terminal inhibits the postsynaptic neuron by means of 2 mechanisms: (1) direct induction of an IPSP, which a GABA-A chloride current typically mediates, and (2) indirect inhibition of the release of excitatory neurotransmitter in the presynaptic afferent projection, typically with a GABA-B potassium current. Once again, alterations or mutations in the different subunits or in the molecules that regulate their function might affect the seizure threshold or the propensity for recurrent seizures.

Defective activation of GABA neurons: GABA neurons are activated by means of feedforward and feedback projections by excitatory neurons. These 2 types of inhibition in a neuronal network are defined on the basis of the time of activation of the GABAergic neuron relative to that of the principal neuron output of the network, such as the hippocampal pyramidal CA1 cell. In feedforward inhibition, GABAergic cells receive a collateral projection from the main afferent projection that activates the CA1 neurons, namely, the Schaffer collateral axons from the CA3 pyramidal neurons. This feedforward projection activates the soma of GABAergic neurons before or simultaneously with activation of the apical dendrites of the CA1 pyramidal neurons.

Activation of the GABAergic neurons results in an IPSP that inhibits the soma or axon hillock of the CA1 pyramidal neurons almost simultaneously with the passive propagation of the excitatory potential (ie, EPSP) from the apical dendrites to the axon hillock. The feedforward projection thus primes the inhibitory system in a manner that allows it to inhibit the pyramidal cell's depolarization and firing of an action potential.

Feedback inhibition is another system that allows GABAergic cells to control repetitive firing in principal neurons, such as pyramidal cells, and to inhibit the surrounding pyramidal cells. Recurrent collaterals from the pyramidal neurons activate the GABAergic neurons after the pyramidal neurons fire an action potential. In the last few years, experimental evidence has indicated that some other kind of interneuron might be a gate between the principal neurons and the GABAergic neurons. In the dentate gyrus, the mossy cells of the hilar polymorphic region appear to gate inhibitory tone and activate GABAergic neurons. The mossy cells receive both feedback and feedforward activation, which they convey to the GABAergic neurons. However, in certain circumstances they appear highly vulnerable to seizure-related neuronal loss.

After some of the mossy cells are lost, activation of GABAergic neurons is impaired.8 Synaptic reorganization is a form of brain plasticity induced by neuronal loss. Formation of new circuits that include excitatory and inhibitory cells has been demonstrated in several animal models and in humans with intractable temporal-lobe epilepsy. Insufficient sprouting that attempts to restore inhibition might alter the balance between excitatory and inhibitory tone in the neural network.

Defective intracellular buffering of calcium: Recurrent seizures induced by a variety of methods result in a pattern of interneuron loss in the hilar polymorphic region in rodents, with striking loss of the neurons that lack calcium-binding proteins parvalbumin and calbindin. In rat hippocampal sections, these interneurons demonstrate a progressive inability to maintain a hyperpolarized resting membrane potential; eventually, they die. An experiment in which researchers used microelectrodes containing the calcium chelator BAPTA demonstrated reversal of the deterioration in the membrane potential as the calcium chelator was allowed to diffuse in the interneuron; the result showed the critical role of adequate concentrations of calcium-binding proteins.9 A postulated contributor is medical intractability in some patients, which may contribute to the abnormally low concentrations or even dysfunction of these proteins.

The end result is the premature loss of interneurons, which alters inhibitory control over the local neuronal network in favor of net excitation. This effect may explain, eg, why 2 patients who have a similar event (eg, simple febrile convulsion) have remarkably dissimilar outcomes: One may have completely normal development, and the other have intractable partial-onset epilepsy after a few years.

Mechanisms leading to increased excitation

Mechanisms leading to increased excitation include increased activation of NMDA receptors, increased synchrony between neurons due to ephaptic interactions, and increased synchrony and/or activation due to recurrent excitatory collaterals.

Increased activation of NMDA receptors: Glutamate is the major excitatory neurotransmitter in the brain. The release of glutamate causes an EPSP in the postsynaptic neuron by activating the glutaminergic receptors AMPA/kainate and NMDA and the metabotropic receptor. Fast neurotransmission is achieved with the first 2 types. The metabotropic receptor alters cellular excitability by means of a second-messenger system with late onset but prolonged duration. The major functional difference between the 2 fast receptors is that the AMPA/kainate receptor opens channels that primarily allow the passage of monovalent cations (ie, sodium and potassium), whereas the NMDA type is coupled to channels that also allow passage of divalent cations (ie, calcium).

Calcium is a catalyst for many intracellular reactions that lead to changes in phosphorylation and gene expression. Thus, it is in itself a second-messenger system. NMDA receptors are generally assumed to be associated with learning and memory. The activation of NMDA receptors is increased in several animal models of epilepsy, such as kindling, kainic acid status, pilocarpine, and other models. Some patients with epilepsy may have an inherited predisposition for fast or long-lasting activation of NMDA channels that alters their seizure threshold. Other possible alterations include the ability of intracellular proteins to buffer calcium, increasing the vulnerability of neurons to any kind of injury that otherwise would not result in neuronal death.

Increased synchrony between neurons due to ephaptic interactions: Electrical fields created by synchronous activation of pyramidal neurons in laminar structures, such as the hippocampus, may increase further the excitability of neighboring neurons by nonsynaptic (ie, ephaptic) interactions. Other possible nonsynaptic interactions include electrotonic interactions due to gap junctions or changes in extracellular ionic concentrations of potassium and calcium.

Increased synchrony and/or activation due to recurrent excitatory collaterals: Neuropathologic studies of patients with intractable partial-onset epilepsy have revealed frequent abnormalities in the limbic system, particularly in the hippocampal formation. A common lesion is hippocampal sclerosis, which consists of a pattern of gliosis and neuronal loss primarily affecting the hilar polymorphic region and the CA1 pyramidal region. These changes are associated with relative sparing of the CA2 pyramidal region and an intermediate lesion in the CA3 pyramidal region with dentate granule cells. Prominent hippocampal sclerosis is found in about two thirds of patients with intractable temporal-lobe epilepsy. Animal models of status epilepticus reproduced this pattern of injury; however, animals with more than 100 brief convulsions induced by kindling seizures had a similar pattern.10

A situation more subtle and apparently more common than that described above is mossy-fiber sprouting.11 Mossy fibers are the axons of the dentate granule cells and typically project into the hilar polymorphic region and the CA3 pyramidal neurons. As neurons in the hilar polymorphic region are lost, their feedback projection into the dentate granule cells degenerates. Denervation due to loss of the hilar projection induces sprouting of the neighboring mossy fiber axons. The net consequence of this phenomenon is the formation of recurrent excitatory collaterals, which increase the net excitatory drive of dentate granule neurons.

The mechanisms discussed here may coexist in different combinations to cause partial-onset seizures. If the mechanisms leading to a net increased excitability become permanent alterations, patients may have pharmacologically intractable partial-onset epilepsy. Currently available medications were developed in acute models of convulsions. In clinical use, they are most effective at blocking propagation of a seizure. Further understanding of the mechanisms that permanently increase net excitability may lead to development of true antiepileptic drugs that alter the natural history of epilepsy.

Generalized-onset seizures

The best-understood example of the pathophysiologic mechanisms of generalized seizures is the thalamocortical interaction that may underlie typical absence seizures. The thalamocortical circuit has normal oscillatory rhythms, with periods of relatively increased excitation and periods of relatively increased inhibition. It generates the oscillations observed, eg, in sleep spindles. The circuitry includes the pyramidal neurons of the neocortex, the thalamic relay neurons, and the neurons in the nucleus reticularis of the thalamus (NRT). Altered thalamocortical rhythms may result in primarily generalized-onset seizures. The thalamic relay neurons receive ascending inputs from spinal cord and project to the neocortical pyramidal neurons. Cholinergic pathways from the forebrain and the ascending serotonergic, noradrenergic, and cholinergic brainstem pathways prominently regulate this circuitry.12

The thalamic relay neurons can have oscillations in the resting membrane potential, which increases the probability of synchronous activation of the neocortical pyramidal neuron during depolarization and which significantly lowers the probability of neocortical activation during relative hyperpolarization. The key to these oscillations is the transient low-threshold calcium channel, also known as T-calcium current. In animal studies, inhibitory inputs from the NRT control the activity of thalamic relay neurons. NRT neurons are inhibitory and contain GABA as their main neurotransmitter. They regulate the activation of the T-calcium channels in thalamic relay neurons because those channels must be de-inactivated to open transitorily.

T-calcium channels have 3 functional states: open, closed, and inactivated. Calcium enters the cells when the T-calcium channels are open. Immediately after closing, the channel cannot open again until it reaches a state of inactivation. The thalamic relay neurons have GABA-B receptors in the cell body and receive tonic activation by GABA release from the NRT projection to the thalamic relay neuron. The result is a hyperpolarization that switches the T-calcium channels away from the inactive state, permitting the synchronous opening of a large population of the T-calcium channels every 100 milliseconds or so.

Findings in several animal models of absence seizures, such as lethargic mice, have demonstrated that GABA-B receptor antagonists suppress absence seizures, whereas GABA-B agonists worsen these seizures.13 Anticonvulsants that prevent absence seizures, such as valproic acid and ethosuximide, suppress the T-calcium current, blocking its channels. One clinical problem is that some anticonvulsants that increase GABA levels (eg, gabapentin, tiagabine, vigabatrin) are associated with an exacerbation of absence seizures. An increased GABA level is thought to increase the degree of synchronization of the thalamocortical circuit and to enlarge the pool of T-calcium channels available for activation.

Frequency

United States

The lifetime likelihood of having at least 1 febrile or nonfebrile epileptic seizure is about 9%, and the lifetime likelihood of receiving a diagnosis of epilepsy is almost 3%. However, the prevalence of active epilepsy is only 0.8%. Hauser and collaborators demonstrated that the annual incidence of recurrent nonfebrile seizures in Olmstead County, Minnesota, was about 100 cases per 100,000 persons aged 0-1 year, 40 per 100,000 persons aged 39-40 years, and 140 per 100,000 persons aged 79-80 years. By the age of 75 years, the cumulative incidence of epilepsy is 3400 per 100,000 men (3.4%) and 2800 per 100,000 women (2.8%).

International

Studies in several countries have shown incidences and prevalences of seizures similar to those in the United States. In some countries, parasitic infections account for the increased incidence of seizures and epilepsy.

Mortality/Morbidity

Regarding morbidity, trauma is not uncommon among people with generalized tonic-clonic seizures. Injuries such as ecchymosis; abrasions; and tongue, facial, and limb lacerations often develop as a result of the repeated tonic-clonic movements. Atonic seizures are also frequently associated with facial and neck injuries. Worldwide, burns are the most common serious injury associated with epileptic seizures.

Regarding mortality, seizures cause death in a small proportion of individuals. Most deaths are accidental due to impaired consciousness. However, sudden unexpected death in epilepsy (SUDEP) may occur even when patients are resting in a protected environment, eg, in a bed with rail guards.

  • The incidence of SUDEP is low, about 2.3 times higher than the incidence of sudden death in the general population. The difference is mostly related to people with long-standing partial-onset epilepsy. The risk of SUDEP rises in people with uncontrolled seizures and probably in people with poor compliance. The risk increases further in people with uncontrolled secondarily generalized tonic-clonic seizures.
  • The mechanism of death in SUDEP is controversial, but suggestions include cardiac arrhythmias, pulmonary edema, and suffocation during an epileptic seizure with impairment of consciousness.
  • Physicians educate patients about seizure precautions. Most accidents occur while patients have impaired consciousness. This is one of the reasons for restrictions on driving, swimming or use of unsupervised bathtub, working at significant heights, and the use of fire and power tools. Treatment with anticonvulsants decreases the likelihood of an accidental seizure-related death.

Sex

See Frequency above.

Age

See Frequency above.



History

The diagnosis of epileptic seizures is made by analyzing the patient's detailed clinical history and by performing ancillary tests for confirmation. Someone who has observed the patient's repeated events is usually the best person to provide an accurate history. However, the patient also provides invaluable details about auras, preservation of consciousness, and postictal states. A key feature of epileptic seizures is their stereotypic nature.

Questions that help clarify the type of seizure include the following:

  • Was any warning noted before the spell? If so, what kind of warning occurred?
    • What did the patient do during the spell?
    • Was the patient able to relate to the environment during the spell and/or does the patient have recollection of the spell?
    • How did the patient feel after the spell? How long did it take for the patient to get back to baseline condition?
    • How long did the spell last?
    • How frequent do the spells occur?
    • Are any precipitants associated with the spells?
    • Has the patient shown any response to therapy for the spells?

Physical

The clinical diagnosis of seizures is based on the history obtained from the patient and, most important, the observers. Physical examination helps in the diagnosis of specific epileptic syndromes that cause abnormal findings, such as dermatologic abnormalities. For example, patients with intractable generalized tonic-clonic seizures for years are likely to have injuries requiring stitches.

Causes

Epileptic seizures are only 1 manifestation of neurologic or metabolic diseases. Epileptic seizures have many causes, including a genetic predisposition for certain seizures, head trauma, stroke, brain tumors, alcohol or drug withdrawal, and other conditions. Epilepsy is a medical condition with recurrent, unprovoked seizures. Therefore, repeated seizures due to alcohol withdrawal are not epilepsy. The causes of most epileptic syndromes are described in several articles of the eMedicine journal, such as those listed below.



Cardioembolic Stroke
Confusional States and Acute Memory Disorders
Febrile Seizures
First Seizure in Adulthood: Diagnosis and Treatment
First Seizure: Pediatric Perspective
Frontal Lobe Epilepsy
Idiopathic Orthostatic Hypotension and other Autonomic Failure Syndromes
Migraine Headache
Somnambulism (Sleep Walking)
Transient Global Amnesia

Other Problems to be Considered

Syncope (eg, cardiac arrhythmia, vasovagal syncope, dysautonomia)
Metabolic conditions (eg, hypoglycemia)
Migraine (eg, migrainous aura, migraine equivalent)
Vascular conditions (eg, transient ischemic attacks)
Sleep disorder (eg, cataplexy, narcolepsy, night terror)
Movement disorder (eg, paroxysmal dyskinesia)
GI conditions (eg, esophageal reflux in neonates and infants)
Psychiatric conditions (eg, conversion, panic attacks, breath-holding
spells, malingering, secondary gain)



Lab Studies

  • Prolactin levels obtained shortly after a seizure have been used to assess the etiology (epileptic or nonepileptic) of a spell.
    • However, the considerable variability of prolactin levels has precluded routine clinical use of such testing.
    • Levels are typically elevated 3- or 4-fold and more likely to occur with generalized tonic-clonic seizures than with other seizure types.
  • Obtaining serum levels of anticonvulsants may help to improve the care for patients with seizures and epilepsy and to answer a clinical question. In practice, the present authors do not advise routine measurement of serum levels. Five recommended indications for the use of serum levels are the situations listed below.

     
    1. Baseline: After seizures are controlled, determine the drug levels needed to achieve seizure-free effectiveness.
    2. Toxicity: Determine the maximal anticonvulsant dose that the patient can tolerate without toxic effects.
    3. Lack of efficacy: Before an anticonvulsant is deemed a failure, knowing whether the patient has achieved an adequate drug level is imperative.
    4. Noncompliance: Approximately 30% of patients miss at least 1 dose of their medication every month.
    5. Autoinduction or pharmacokinetic change: After an anticonvulsant is used for several weeks, the baseline trough serum concentration slowly decreases because of hepatic autoinduction. This phenomenon is most often seen with carbamazepine, oxcarbazepine, and lamotrigine. Adding medications might substantially change the clearance of some anticonvulsants.
  • Like any medical test, serum concentrations of anticonvulsants help in making clinical decisions, but the patient's individual response should be the main consideration.
    • For example, a patient with JME might be seizure free with a valproic acid level of 30 mcg/mL, which is typically considered subtherapeutic. Therefore, clinical judgment regarding how well the patient is doing (ie, no seizures, no adverse effects) should prevail over a laboratory reading.
    • The usual therapeutic ranges include peak and trough levels of a group of adult patients. If the problem under study is toxicity, a peak level is desirable. However, in most circumstances, a trough level is the best indication of efficacy.

Imaging Studies

  • Two studies must be performed after a seizure: neuroimaging (eg, brain MRI, head CT scan) and EEG.
    • A neuroimaging study, such as brain MRI or head CT scan, provides evidence about structural abnormalities that could be the cause for a seizure.
    • If the patient has normal findings on neurologic examination and his or her condition (eg, cognitive, motor) returns to the usual baseline level, the preferred study is a brain MRI because of its resolution to depict subtle abnormalities.
    • Brain MRIs obtained with thin coronal sections by using fast spin-echo (FSE) or inversion recovery (IR) sequences from the presumed region of epileptogenic aura are useful for assessing cortical lesions, which may be amenable to potentially curative surgery.
    • Not every brain MRI study provides the same quality of information. Brain MRI studies obtained at 3.0 Tesla scanners might show better resolution that conventional 1.5 T scanners, or the "open-sided" scanners of 0.5 T.
  • See Presurgical Evaluation of Medically Intractable Epilepsy for additional discussion regarding imaging studies.

Other Tests

  • Electroencephalography
    • Interictal epileptiform discharges or focal abnormalities strengthen the diagnosis and provide some help in determining the prognosis.
    • Although the criterion standard for diagnosis and classification of epileptic seizures includes the interpretation of sleep-deprived EEG, the clinical history remains the cornerstone for the diagnosis of epileptic seizures.
  • Video-EEG
    • Video-EEG monitoring might be needed to establish a definitive diagnosis of spells with impairment of consciousness.
    • This test can be performed to rule out an epileptic etiology with a high degree of confidence if the patient has demonstrable impairment of consciousness during the spell in question.
    • Video-EEG monitoring is also used to characterize the type of seizure and epileptic syndrome to optimize pharmacologic treatment and for presurgical workup.

Procedures

  • Lumbar puncture for CSF examination has a role in the patient with obtundation or in patients in whom meningitis or encephalitis is suspected.

Histologic Findings

Epileptic seizures have many causes. Some epileptic syndromes have specific histopathologic abnormalities. For further discussion, refer to the articles about specific epileptic syndromes listed in the Introduction.



Medical Care

The goal of treatment is to achieve a seizure-free status without adverse effects. This goal is accomplished in more than 60% of patients who require treatment with anticonvulsants. However, many people have adverse effects, and some have seizures that are refractory to medical therapy. Monotherapy is important because it decreases the likelihood of adverse effects and avoids drug interactions. In addition, monotherapy may be cheaper than polytherapy, as many of the anticonvulsants have hepatic enzyme–inducing properties that decrease the serum level of the concomitant drug, increasing the required dose of the concomitant drug.

People with seizures experience psychosocial adjustments after their diagnosis; therefore, social and/or vocational rehabilitation may be needed. Many physicians underestimate the consequences that epilepsy may have on patients. For instance, patients with epilepsy may live in fear of experiencing the next seizure, and they may be unable to drive or work at heights.

Special situations in which treatment is needed

  • The mainstay of therapy for people with recurrent unprovoked seizures is an anticonvulsant. If a patient has had more than 1 seizure, administration of an anticonvulsant is recommended. On the contrary, standard of care for a single, unprovoked seizure is avoidance of typical precipitants (eg, alcohol, sleep deprivation); no anticonvulsants are recommended unless the patient has risk factors for recurrence.
  • The risk of recurrence in the 2 years after a first unprovoked seizure is 15-70% depending on several factors, mainly an abnormal brain MRI, an abnormal sleep-deprived EEG, and a partial-onset seizure.
    • The abnormal brain MRI finding refers to a possible substrate for an epileptogenic zone; therefore, it most often suggests that the brain injury that led to epilepsy is in the cortical and limbic regions. Diffuse abnormalities, such as hydrocephalus, might increase the risk by injuring the cerebral cortex.
    • An abnormal sleep-deprived EEG can include any or several abnormalities: epileptiform discharges, focal slowing, diffuse background slowing, and intermittent diffuse intermixed slowing. Epileptiform abnormalities and focal slowing are associated with an increased risk of seizure recurrence compared with the other findings. Nevertheless, the risk of recurrence in a person with 1 generalized tonic-clonic seizure, a normal EEG, a normal brain MRI, and no evidence of focal onset is about 15%; this patient is not treated. If a patient has all risk factors, the risk is approximately 80%; this patient is treated.
  • The major unresolved question is how to treat patients with 1 abnormality with a risk of 30-50%. When the present authors have such a patient, they discuss the possibilities, including risk of seizure recurrence, risk of toxic effects from taking the anticonvulsant, and benefits of avoiding another seizure, with the patient. The authors also discuss seizure precautions, including not driving for a specific time. Treatment with anticonvulsants does not alter the natural history of seizure recurrence; it only masks the risk for the duration of treatment.
  • The First Seizure Trial Group randomly selected 397 patients with an unprovoked, generalized tonic-clonic first seizure to take a conventional anticonvulsant (ie, carbamazepine, phenobarbital, phenytoin, valproic acid) or no treatment.14 About 18% of treated patients had seizure recurrence in 1 year, compared with 39% of untreated patients. Therefore, patients must be told that anticonvulsants reduce the risk of their having another seizure but that anticonvulsants do not totally stop seizures from recurring.

Treatment with anticonvulsants

  • The mainstay of treatment is anticonvulsant medication.
  • The type of seizure and the specific epileptic syndrome play a role in the selection of anticonvulsants, probably because of the different pathophysiologic mechanisms.
  • Some anticonvulsants (eg, lamotrigine, topiramate, valproic acid, zonisamide) have multiple mechanisms of action, and some (eg, phenytoin, carbamazepine, ethosuximide) have only 1 known mechanism of action. Anticonvulsants can be divided into 8 large groups based on their mechanisms, as follows:
    1. Blockers of repetitive activation of sodium channel - Phenytoin, carbamazepine, oxcarbazepine
    2. GABA enhancers - Phenobarbital, benzodiazepines
    3. Glutamate modulators - Topiramate, lamotrigine, felbamate
    4. T-calcium channel blockers - Ethosuximide, valproate
    5. N- and L-calcium channel blockers - Lamotrigine, topiramate, zonisamide, valproate
    6. H-current modulators - Gabapentin, lamotrigine
    7. Blockers of unique binding sites - Gabapentin, levetiracetam
    8. Carbonic anhydrase inhibitors - Topiramate, zonisamide

Anticonvulsive treatments for specific types of seizures

  • Absence seizures: If only absence seizures are present, most neurologists treat them with ethosuximide. If absence seizures are present with other types (eg, generalized tonic-clonic seizures, myoclonic seizures), the choices are valproic acid, lamotrigine, or topiramate. Do not use carbamazepine, gabapentin or tiagabine because they might exacerbate absence seizures. Whether pregabalin, a medication related to gabapentin, might also exacerbate this type of seizure is uncertain.
  • Tonic or atonic seizures: Tonic or atonic seizures typically indicate clinically significant brain injury. The Lennox-Gastaut syndrome is 1 common example of tonic seizures and best treated with broad-spectrum drugs (eg, valproic acid, lamotrigine, topiramate) or felbamate as last resort. Clinical trials of levetiracetam and zonisamide are being conducted. Other modalities include the use of vagal nerve stimulation (VNS).
  • Myoclonic seizures: This seizure has a bimodal distribution. Infants with myoclonic epilepsies usually have a poor prognosis; however, in late childhood and adolescence, the syndrome of JME is often the cause of myoclonic seizures. JME is typically a benign process that is treated easily, but it has a high recurrence rate of approximately 80-90% after discontinuation of anticonvulsants. The best medications for JME and myoclonic seizures are valproic acid, lamotrigine, and topiramate. Levetiracetam has been FDA-approved for adjunctive therapy. Anecdotal evidence suggests that zonisamide might be helpful in JME.
  • Primary generalized tonic-clonic seizures: This seizure type responds to valproic acid, topiramate, or lamotrigine. Levetiracetam has gained recent FDA approval as adjunctive therapy.
    • The Generalized Seizures arm of the SANAD trial demonstrated that "Valproate is better tolerated than topiramate and more efficacious than lamotrigine, and should remain the drug of first choice for many patients with generalised and unclassified epilepsies. However, because of known potential adverse effects of valproate during pregnancy, the benefits for seizure control in women of childbearing years should be considered."15 Levetiracetam and zonisamide were not included in this trial, which only tested lamotrigine, topiramate and valproate.
  • Partial-onset seizures: Carbamazepine is considered first-line therapy. However, in special populations, lamotrigine, oxcarbazepine, and topiramate might be better choices. Adjunctive therapy with levetiracetam, tiagabine, gabapentin, or pregabalin might be a choice if the first or second monotherapy trial with first line treatments failed.
    • The Veterans Administration (VA) Cooperative Study I clearly demonstrated similar efficacies for carbamazepine, phenytoin, primidone, and phenobarbital. Carbamazepine and phenytoin were tolerated better by men than women.16
    • The VA Cooperative Study II showed that carbamazepine and valproic acid had similar efficacies. However, in subset analysis for complex partial seizures, carbamazepine might be a better choice than valproate.17
    • The VA Cooperative Study of the treatment of seizures in the elderly (patients aged 60 y or older) was a comparison of carbamazepine, lamotrigine, and gabapentin. Lamotrigine and gabapentin were better tolerated than carbamazepine and similarly effective. Gabapentin cause more adverse effects than lamotrigine. The results led to the recommendation of lamotrigine as first-line monotherapy in elderly patients.18
    • The Partial Seizures arm of the SANAD trial demonstrated that "Lamotrigine is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure outcomes and is therefore a cost-effective alternative for patients diagnosed with partial onset seizures."19 This trial included carbamazepine, gabapentin, lamotrigine, oxcarbazepine, and topiramate.
    • All new medications have been tested as adjunctive therapy, and head-to-head comparisons between new drugs and carbamazepine have been conducted in Europe. In general, the new drugs have similar statistical efficacies but fewer adverse effects than carbamazepine. The American Academy of Neurology and the American Epilepsy Society assembled a task force that reviewed the literature and provided evidence-base recommendations for monotherapy, adjunctive therapy, treatment of primary generalized seizures, treatment in children, and treatment of subgroups of new-onset and refractory epilepsy.20, 21 Of the new anticonvulsants, lamotrigine and topiramate appeared to have broad spectrum of action in many seizure types.
    • If carbamazepine fails to control the seizures, lamotrigine, topiramate, tiagabine, gabapentin, levetiracetam, oxcarbazepine, pregabalin and zonisamide are considered for second- or third-line therapy. Several new anticonvulsants, including lamotrigine, topiramate, and oxcarbazepine, are indicated as monotherapy.
    • Although the new anticonvulsants are considered second- or third-line therapy, they can be used as first-line therapy in some patients.
    • Discussing the adverse-effect profiles of anticonvulsants with patients is important, because the efficacies of anticonvulsants appear to be similar.
  • Future advancements will involve antiepileptic drugs that alter the natural history of epilepsy. Evidence in animal models of epilepsy suggests that at least 2 of the current anticonvulsants, topiramate and levetiracetam, have neuroprotective effects and that they might slow the natural history of epilepsy. However, the applicability of animal data to human patients is unknown.

Anticonvulsive treatments for different patient populations:

  • The use of anticonvulsants is slightly different in several populations of patients, including neonates, children, elderly patients, pregnant women, and patients with hepatic or renal insufficiency.
  • Neonates and children: Children and neonates tend to require similar loading doses per kilogram of body weight, but they tend to metabolize the drugs faster than adults. They also have rapid increases in the total volume of distribution.
  • Elderly patients: Elderly patients present the opposite problem to that of neonates and children. Slowed hepatic metabolism, decreased renal clearance, and decreased volumes of distribution are normal features of the aging process. These features mean a need for lowered initial and maintenance doses in elderly adults.
  • Women's issues: Enzyme-inducing anticonvulsants, such as carbamazepine, phenytoin, phenobarbital, primidone, felbamate, lamotrigine, topiramate, and oxcarbazepine, decrease the efficacy of birth control pills. Some anticonvulsants cause this drug interaction in a dose-dependent manner, with a negligible effect at low doses. Some obstetricians use a high-dose estrogen-progesterone pill. An alternative and possibly preferred approach is to use a second method of contraception.
    • Woman of childbearing age should take folic acid at least 1 mg/d to decrease the rate of neural-tube malformations in the fetus.
    • Evidence strongly suggests that, during pregnancy, women should take the medication that best controls their epilepsy. Switching medications during pregnancy is not recommended because of the risk of losing seizure control.
    • Women should be treated with only 1 anticonvulsant rather than polytherapy. Data from Japan show an exponential risk of birth defects as anticonvulsants are added in polytherapy.
    • Drug serum levels should be obtained frequently because of the many physiologic changes that take place during pregnancy, including changes in volume of distribution, protein binding, and hepatic metabolism and erratic absorption. In particular, decreased serum concentration of lamotrigine in the third trimester is well documented.
    • The performance of amniocentesis is a personal decision between the woman and her obstetrician. The most important point is to have a clear idea about how the information obtained will be useful for clinical decision making.
  • Hepatic and renal insufficiency: Considerable data are available on the use of phenytoin in both conditions. However, phenytoin is not a preferred medication because of its nonlinear kinetics, hepatic autoinduction, numerous drug interactions, and high degree of protein binding. Among all anticonvulsants, phenytoin, valproic acid, and felbamate have been associated with acute hepatic injury. Gabapentin and levetiracetam are excreted mostly by means of renal clearance. Their doses could be adjusted for renal insufficiency. They are useful in patients with hepatic failure, especially when a drug-induced etiology is suspected. Lamotrigine, which is metabolized by means of glucuronidation, a phase II reaction, is also used in some patients with hepatic insufficiency.

Nonpharmacologic treatments

  • Diet: The ketogenic diet has a role in children with severe epilepsy. One major problem is that, despite television programs and a movie supporting its use, <10% of patients continue the diet after a year. Furthermore, any small carbohydrate intake (eg, lollypop, piece of candy) resets ketone metabolism for 2 weeks, eliminating antiseizure efficacy. The diet, which relies heavily on Crisco (shortening product), is difficult to maintain. The diet is unquestionably effective in some refractory cases, but the present authors do not consider this treatment in teenagers or adults unless all of their intake is being delivered by means of a gastric tube.
  • VNS: The VNS is a palliative device approved to treat medically refractory partial-onset epilepsy in adults. Some studies demonstrate its efficacy in partial-onset seizures and in a small number of patients with primary generalized epilepsy. Randomized studies showed modest efficacy at 3 months, but postmarketing experience shows delayed improvement in another group of patients. According to the manufacturer's registry, efficacy of the device at 18 months is 40-50%, where efficacy is defined as a reduction in seizures of 50% or more. Many patients report improvement in seizure intensity and general mood. However, seizure-free rates for pharmacologically intractable partial-onset epilepsy are <10%.

Discontinuation of anticonvulsants

  • After a person has been seizure free for typically 2-5 years, physicians consider discontinuing the medication. Many patients outgrow many epileptic syndromes of childhood and need not take anticonvulsants. On the contrary, the recurrence rate during adulthood for patients with JME is about 80-90% in 2 years despite many years of being seizure free with low doses of appropriate anticonvulsants. The relapse rate for adults is about 40-50%; for children, it is about 25%. This difference is probably due to the different epileptic syndromes that are prevalent in the 2 populations.
  • Many neurologists use the risk factors for new-onset seizures to assess patients for discontinuation of anticonvulsants. A normal sleep-deprived EEG and normal brain MRI lower the risk of relapse after discontinuation, whereas epileptiform or focal abnormalities on a sleep-deprived EEG and/or focal cortical abnormalities on a brain MRI significantly increase the risk.
  • Other factors associated with an increased risk of seizure recurrence after discontinuation include the following:
    • Abnormal EEG (worse if epileptiform discharges or focal abnormalities are present)
    • Abnormal brain MRI (especially injury in cortical and limbic regions)
    • Several seizure types (worse if tonic or atonic seizures are present)
    • High number and frequency of seizures
    • Long duration of epilepsy before the seizures are controlled
    • Short duration of seizure freedom
  • About 75% of relapses after discontinuation occur in the first year, and at least 50% of patients who have another seizure do so in the first 3 months. Therefore, advise the patients to observe strict seizure precautions (including not driving) during tapering and for at least 3 months after discontinuation, depending on state laws. Driving is an impediment in some patients, who may opt to continue therapy.
  • The present authors recommend that all anticonvulsants, except primidone, phenobarbital, and benzodiazepines, be gradually discontinued over 6-10 weeks, if they were used for a long period. Discontinue primidone, phenobarbital, and benzodiazepines over 10-16 weeks.

Surgical Care

  • The 2 major kinds of brain surgery for epilepsy are palliative and potentially curative.
    • A few years ago, the most common palliative surgery was anterior callosotomy. This surgery has been indicated for patients with intractable atonic seizures, who often have facial and neck injuries due to a fall. This surgery is still performed but rarely. The use of a VNS in such patients has reduced the need for anterior callosotomy.
    • Several curative surgeries are possible, including lobectomy and lesionectomy.
      • In general, the epileptogenic zone must be mapped by using video-EEG monitoring with intracranial electrodes unless the patient clearly has a unilateral temporal-lobe onset.
      • Outcomes of temporal-lobe surgeries are better than those for surgeries in other areas. If a patient has unilateral temporal-lobe seizures (as observed on video-EEG) and unilateral hippocampal sclerosis (as observed on brain MRI), the likelihood of a class I outcome (no seizures or only auras) at 2 years is 85%.
      • If another anticonvulsant is attempted in the same patient with medically refractory epilepsy, the likelihood of a class I outcome is <5% at 2 years. A patient with medically refractory epilepsy is one in whom 3 anticonvulsants with adequate serum concentrations fail because of lack of efficacy and not because of adverse effects. After 3 anticonvulsants fail, patients with partial-onset seizures should be referred to an epileptologist.
  • For further details concerning surgical treatment of epilepsy please refer to the articles Identification of Potential Epilepsy Surgery Candidates, Outcome of Epilepsy Surgery, and Presurgical Evaluation of Medically Refractory Epilepsy.

Consultations

  • The first level of referral is for diagnosis and treatment.
    • Consult a neurologist if recurrent spells have not been diagnosed or if they have not responded to conventional therapy with a first or second anticonvulsant.
    • Establishing the correct diagnosis is the first step in providing adequate treatment.
  • The second level of referral is to an epileptologist: Patients in whom at least 2, and preferably 3, anticonvulsants at adequate serum concentrations have failed should be referred to an epileptologist to consider all available therapies, including pharmacologic, dietary, and surgical treatments.

Diet

The ketogenic diet is an effective tool to improve seizure control in very select cases. It is very difficult to follow as it requires achieving a ketotic state. Fewer than 1 in 20 patients who started this diet will be following it a year later.

Anecdotal data is published about improvement of seizure frequency following the Atkins diet and taking fewer than 10 g of carbohydrates, but the data is only preliminary.22

Activity

The major problem for patients with seizures is the unpredictability of the next seizure. Five types of seizure precautions should be discussed with patients who have seizures, as listed below. These lifestyle precautions are clearly more applicable to some patients than others. Safety must be balanced with the risk for seizures. A patient with many poorly controlled, diurnal seizures might exercise more caution than a patient who has only nocturnal seizures.

  • Driving motorized vehicles: Recommendations vary depending on state laws and on whether the patient has seizures that occur exclusively during sleep. Consult current state and federal laws and regulations. For example, to resume commercial driving across state lines, a patient must have a 5-year seizure-free period. The recommendation for driving cars and trucks extends to the operation of other motorized vehicles, such as boats, motorcycles, and others. Aircraft pilots are typically no longer permitted to fly.
  • Water precautions: Common sense dictates that patients should not swim alone, and patients with seizures should be particularly aware being in the presence of an adult lifeguard who can pull them out of the water if needed. Wearing a life jacket in a boat is important. Activities as simple as taking a bath might be risky because a patient can drown with as little as an inch of water during the flaccid postictal phase. Patients who might have a seizure, eg, while waiting for the water to warm up, may have hot-water burns.
  • Heights: Patients with seizures might experience one, eg, while trying to fix a roof or during another activity at considerable height from floor.
  • Fire: Burns from injuries related to cooking are not uncommon.
  • Power tools: Caution with the use of power tools is required. In particular, supervision during their use is needed, and the use of safety devices, such as automatic shutoff switches, is recommended.



The anticonvulsant of choice depends on an accurate diagnosis of the epileptic syndrome. Please see the Medical Care section and refer to medications in the appropriate articles listed in the Introduction for specific types of epileptic seizures or syndromes.



Transfer

  • Refer patients with intractable spells to a neurologist or an epileptologist for further workup, including video-EEG monitoring, to characterize the etiology of their seizures.

Deterrence/Prevention

  • Encourage the use of helmets to prevent head trauma while the patient is biking, skiing, riding a motorcycle, or participating in other activities.

Prognosis

  • The patient's prognosis for disability and for a recurrence of epileptic seizures depends on the type of epileptic seizure and the epileptic syndrome in question.
  • See the other articles listed in the Introduction regarding specific epileptic syndromes.

Patient Education

  • Epilepsy Foundation of America has a large library of educational materials that are available to health care professionals and the general public.
  • The American Epilepsy Society is the professional organization of people who take care of patients with epilepsy. Their Web site provides a large amount of credible information.
  • For excellent patient education resources, visit eMedicine's Brain and Nervous System Center. Also, see eMedicine's patient education article Epilepsy.



Medical/Legal Pitfalls

  • Inappropriate diagnosis
    • The diagnosis of seizures is based on the clinical history.
    • Because many types of seizures are associated with impairment of consciousness, patients are unaware of their occurrence. The history as related by a witness is of high importance.
    • The clinical diagnosis can be confirmed by abnormalities on the interictal EEG, but these abnormalities could be present in otherwise healthy individuals, and their absence does not exclude the diagnosis of epilepsy.
    • Video-EEG monitoring is the criterion standard for classifying the type of seizure or syndrome or to diagnose pseudoseizures. However, it is expensive and laborious study; therefore, monitoring all patients is impractical. Only those whose condition does not respond to treatment should undergo video-EEG. Referral to an epilepsy center should be reserved for patients whose seizures are refractory to treatment. Some frontal-lobe seizures are considered pseudoseizures for many years until appropriate diagnosis is made by means of video-EEG.
    • Not all spells are seizures.
  • Liability of having seizures
    • Patients who have lapses of consciousness during wakefulness and in whom seizures are suspected should be educated and warned about seizure precautions.
    • Documenting on the patient's chart that driving and occupational hazards for people with seizures were discussed is useful.
    • Physicians should be aware of the state regulations regarding driving, which vary considerably among states and nations.

Special Concerns

  • To avoid unnecessary injury, people who have epileptic seizures and other spells of sudden-onset seizures should be given restrictions for driving, ascending heights, working with fire or cooking, using power tools, taking unsupervised baths, and swimming.
  • The restrictions differ for each patient because of the individual features of the seizures; the degree of seizure control; and, in the United States, state laws. Other countries have more permissive or more restrictive laws regarding driving.


REFERENCES

Section 10 of 10 Click here to go to the previous section in this topic Click here to go to the top of this page